Introduction
Virtually all patients with multiple myeloma (MM) eventually relapse. Relapsed disease is characterized by increasingly shorter periods of remission following each salvage therapy. 1 Survival among MM patients in whom novel agents (including bortezomib [BORT] , lenalidomide [LEN] , and/or thalidomide) have failed is especially poor. 2 There is a clear unmet need for new treatments, particularly for patients who are relapsed and refractory to novel agents.
Pomalidomide (POM) is a distinct immunomodulatory drug with potent antimyeloma activity. [3] [4] [5] POM plus dexamethasone (DEX) has synergistic antiproliferative effects in LEN-resistant myeloma cells. 6 The activity of POM in cells resistant or refractory to LEN may be due to important differences in both the potency of the drugs and their respective mechanisms of action. 3, [7] [8] [9] [10] [11] POM has demonstrated efficacy in patients with relapsed/refractory MM (RRMM) who had received multiple prior therapies, either when given alone [12] [13] [14] or with low-dose DEX (LoDEX). [14] [15] [16] [17] Here we report the results of a multicenter, randomized, open-label phase 2 trial. The phase 1 part of the study established the maximum tolerated dose (MTD) of POM (4 mg/day on days 1-21 of a 28-day cycle). 18 The phase 2 part evaluated the efficacy and safety of POM when given alone or in combination with LoDEX in RRMM patients.
Methods
MM-002 is a phase 1/2 trial conducted at 18 centers in the USA and Canada, initiated in December 2009.
This manuscript reports on the phase 2 part, which was an open-label, randomized trial; phase 1 results have already been reported. 18 Eligible patients were aged ≥ 18 years, had RRMM, and had measurable M-paraprotein levels in serum or urine. All patients had received regimen, as well as have disease progression during or within 60 days (measured from the end of the last cycle) of completing treatment with the last regimen used prior to study entry (and thus had relapsed and refractory disease). Disease progression was defined as any of the following: increase in serum monoclonal paraprotein and/or urine paraprotein; increase in bone marrow plasmacytosis and plasma cells; appearance of new soft-tissue plasmacytomas or increase in size of existing plasmacytoma(s); new lytic bone lesions or an increase in the size of the existing bone lesions; or the development of hypercalcemia (serum calcium > 11.5 mg/dL). Exclusion criteria were absolute neutrophil count (ANC) < 1000/µL; platelet count < 75 000/µL or < 30 000/µL for patients in whom < 50% or ≥ 50% of bone marrow nucleated cells were plasma cells, respectively; serum creatinine ≥ 3.0 mg/dL; serum liver transaminase levels > 3.0 × the upper limit or normal; or serum bilirubin > 2.0 mg/dL. Concomitant intravenous amino-bisphosphonate therapy was permitted.
Patients were randomized (1:1) to POM (4 mg/day on days 1-21 of each 28-day cycle) alone or with LoDEX (40 mg/week), using an interactive voice response system. Treatment continued until disease progression or unacceptable toxicity. At progression, patients assigned to POM alone could add LoDEX.
All patients received aspirin (81-100 mg daily) unless contraindicated. If aspirin was contraindicated, patients received another form of antithrombotic therapy according to local hospital guidelines or physician preference. Erythroid growth factors, bisphosphonates, platelet and/or red blood cell transfusions, and granulocyte colony-stimulating factor (G-CSF; if ANC < 1000/µL) were allowed. The efficacy evaluable population included all patients who received The primary endpoint was progression-free survival (PFS), defined as the time from randomization to the first documentation of disease-progression or death from any cause. Secondary endpoints included overall response rate (ORR; defined as partial response or better [≥PR]), time-to-response and duration of The intent-to-treat (ITT) population (all randomized patients) was used for PFS and OS data, the efficacy evaluable population for response, and the safety population (patients who received 
Results
The protocol-specified final analysis was performed at 100% information, when 167 patients across both treatment arms had disease progression or had died during the study, with a median follow-up of 9.4 months (data cut-off April 1, 2011). Updated data were available after a median follow-up of 14. 
Patients and treatment
A total of 221 patients were randomized to POM+LoDEX (n = 113) or POM (n = 108) ( Figure 1 ). Two patients were randomized but never received study drug and were therefore excluded from the safety The median age was 63 years (range, 34-88 years), with 59% of patients aged ≤ 65 years. Most patients (81%) were white, 54% were male, and 27% had high-risk cytogenetics ( Table 1 ). The median number of prior therapies was 5 (range, 1-13); all patients had received prior LEN and BORT, 99% had received prior DEX, 67% had received prior thalidomide, 75% had undergone prior stem cell transplantation, and 23% had received prior carfilzomib (CFZ). Overall, 62% of patients were refractory to both LEN and BORT. A total of 219 patients received ≥ 1 dose of study drug and were included in the safety population.
The median number of treatment cycles was 5 (range, 1-38); median treatment duration was 5 months. Of the 108 patients assigned to POM alone, 65 (60%) received LoDEX at disease progression. Per prespecified one-sample binomial test, the response rate in the POM+LoDEX arm was considered to be statistically significantly effective whereas the response rate in the POM arm was not. The ORR (≥PR) was 33% in the POM+LoDEX group and 18% in the POM alone group (odds ratio = 2.28, 95% CI, 1.21-4.29, P = .013); minimal response or better was achieved in 45% and 31% of patients, respectively ( In the POM+LoDEX group, the median duration of study treatment was longer for patients who achieved ≥ PR, compared with their last prior therapy (11.9 vs 4.2 months, respectively) and responses were consistently observed regardless of refractoriness to LEN. Of the responders who had a longer duration of study treatment, 76% had a better response to POM+LoDEX than to their last prior therapy. Patients who achieved ≥ PR in the POM alone group also had a longer median duration of study treatment than with their last prior therapy (16.6 vs 6.4 months, respectively). Of the responders who had a longer duration of study treatment, 86% had a better response to POM alone than to their last prior therapy.
Efficacy

Special populations.
Outcomes with POM+LoDEX were consistent regardless of age. Median PFS was 4.7 months in patients aged ≤ 65 years and 3.7 months in those > 65 years; ORRs were 31% and 35%, and median response durations were 10.1 and 7.7 months, respectively. POM+LoDEX showed promising activity in the 30 patients with t(4;14) and/or del (17p) cytogenetic abnormalities: median PFS was 3.1 months, ORR was 23%, and median response duration was 4.9 months LEN-refractory disease. For patients with LEN-refractory disease (n = 174), median PFS was 3.8 months with POM+LoDEX and 2.2 months with POM alone (HR = 0.72, 95% CI, 0.52-0.99, P = .042) ( Figure   2C ). ORRs were 30% and 21%, respectively (P = .224) ( Table 2 ). Median duration of response was 7.7 and 8.8 months, and median OS was 16.0 and 12.0 months, respectively (HR = 0.96, 95% CI, 0.68-1.34, P = .793) ( Figure 2D ).
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From LEN-and BORT-refractory disease. Among patients with disease refractory to both LEN and BORT (n = 136), median PFS was 3.8 months with POM+LoDEX and 2.0 months with POM alone (HR = 0.77, 95% CI, 0.53-1.11, P = .150) ( Figure 2E ). ORRs were 31% and 21%, respectively (P = .243) ( Table 2 ).
Median duration of response was 6.5 and 11.4 months in the POM+LoDEX and POM alone groups, respectively. Median OS was 13.4 and 12.5 months, respectively (HR = 1.05, 95% CI, 0.71-1.54, P = .814) ( Figure 2F ). 
Safety
The most common grade 3-4 AE was neutropenia, which occurred in 41% of patients treated with POM+LoDEX and 48% of patients treated with POM alone (Table 3 ). The incidence of grade 3-4 febrile
was low in the POM+LoDEX and POM alone groups (3% and 5%, respectively). The most common grade 3-4 nonhematologic AE was pneumonia (22% with POM+LoDEX and 15% with POM alone). In the POM+LoDEX group, 27% of the cases of any grade pneumonia were also associated with dyspnea (any grade). The incidence of any grade deep-vein thrombosis (DVT) was low (2% with POM+LoDEX and 3% with POM alone) and there were no cases of grade 3-4 peripheral neuropathy.
During study treatment, approximately 50% of patients received G-CSF and approximately 20% received erythroid growth factors (Table 3 ). Platelet and red blood cell transfusions were required in 17% and 47% of patients. Approximately one-third of patients required ≥ 1 POM dose reduction (29% with POM+LoDEX and 36% with POM alone), although dose reductions or interruptions due to neutropenia and thrombocytopenia were infrequent ( Table 3 ). The rate of POM discontinuation due to treatmentrelated AEs was 3% (2% in the POM+LoDEX group and 5% in the POM group). The most common AEs leading to discontinuation of POM+LoDEX were renal failure and increased blood creatinine.
Of the 19 deaths that occurred during the study period, 10 occurred in the POM+LoDEX group and 9 in the POM alone group; the majority of deaths were attributed to MM and disease progression. and led to an impressive ORR of 33% (P = .013). Responses were durable with both POM+LoDEX and POM alone. Median OS was 16.5 and 13.7 months in the POM+LoDEX and POM groups, respectively, which compares favorably with historically reported 9-month survival rates for patients in whom currently approved novel therapies have failed. 
org From
This study confirmed the efficacy and safety of POM when used at the MTD (4 mg/day on days 1-21 of each 28-day cycle) established in the phase 1 part of the study. 18 Furthermore, the present study employed a "randomized design" to evaluate 2 experimental schedules. 21 This showed ORRs of 33% with
POM+LoDEX compared with 18% in the POM alone arm, which confirmed the synergistic effect of POM+LoDEX as observed in previous in vitro studies. 6 LoDEX alone is not effective in this population of RRMM patients and, therefore, was not chosen as the comparator; POM+LoDEX was selected as the active arm in the subsequent phase 3 study of patients with advanced MM who had exhausted BORT and LEN treatment. The latter study further confirmed the benefits of POM+LoDEX in terms of PFS (4.0 months) and OS (12.7 months) versus high-dose DEX, the standard of supportive care (PFS 1.9 months and OS 8.1 months). 22 Trials evaluating POM plus steroid-based regimens will assess whether the treatment of RRMM patients can be further advanced.
23-28
The efficacy of POM+LoDEX was not affected by prior treatment; POM+LoDEX was as effective in patients who had received LEN-based treatment as their last prior therapy and who had disease which was refractory to LEN or both LEN and BORT. 29 These findings replicate previous phase 2 studies [15] [16] [17] and have now been confirmed by phase 3 data. 22 Thus, there is currently no clinical evidence of crossresistance between POM and LEN. We also found an ORR of 37% with POM+LoDEX in patients who had received previous CFZ. This is of particular interest as, in a similar population of RRMM patients (although less stringently defined because patients with SD on last therapy could be included), treatment with CFZ resulted in ORRs of 15%, with a duration of response of 7.8 months and a median OS of 11.9 months. 30 Patients with the cytogenetic abnormalities t(4;14) and/or del (17p) have poor prognosis and represent an additional unmet medical need. [31] [32] [33] POM+LoDEX resulted in an ORR of 23%, with a median response duration of 4.9 months in this subgroup, suggesting encouraging activity in patients with high-risk The primary AEs observed with POM, with or without LoDEX, were neutropenia, thrombocytopenia, and anemia. The incidence of infections was higher with POM+LoDEX than with POM, but the incidence of DVT, which is generally increased when LEN or thalidomide are combined with DEX, [34] [35] [36] [37] was low (2%), with relatively simple thromboprophylaxis consisting mainly of oral aspirin (81-100 mg/day).
Importantly, none of the patients developed grade 3-4 peripheral neuropathy, and other nonhematologic AEs were generally mild to moderate. With appropriate management, the rates of discontinuations due to treatment-related AEs were low (2-3%).
A potential limitation of this study is the open-label design, which may result in a bias in PFS assessment.
A further limitation is that many patients (60%) assigned to POM received POM+LoDEX at progression, making it difficult to isolate the POM effect. In addition, the median PFS observed in this study (2.7-4.2 months) was also shorter than the original assumption of clinical relevance used for the power calculation (6.0-10.0 months). However, the sample size and power were based on comparison between the two groups, which was close to the protocol assumption (POM+LoDEX vs POM; HR = 0.60 per protocol vs observed HR = 0.68), and the difference remained statistically significant at the final analysis (P = .003).
In conclusion, this study confirms the synergistic action of POM+LoDEX and shows encouraging clinical efficacy in patients with RRMM who have exhausted multiple prior therapies, including BORT and LEN.
The limited cross-resistance between POM and LEN supports the effectiveness of sequential use of immunomodulatory drugs, as well as combinations. [38] [39] [40] Therefore, POM-based combination therapy 
